Which Medications Cannot Be Taken with Rifampin?

Rifampin is a powerful antibiotic used primarily to treat tuberculosis and certain other bacterial infections. Because of the way it works in the body, it interacts with many other medications—sometimes dangerously. According to FDA-sourced drug labeling, at least 10 medication classes or individual drugs are contraindicated (not recommended for use) with rifampin. These include clozapine, atovaquone, ritonavir-boosted saquinavir, ticagrelor, ranolazine, doravirine, lorlatinib, estradiol/dienogest birth control, fosamprenavir, and others. The reason: rifampin is a potent CYP3A4 enzyme inducer, meaning it speeds up the breakdown of many other drugs in the liver, reducing their effectiveness to dangerous levels—or, in some cases, causing severe toxicity through paradoxical mechanisms. This guide explains those documented interactions, how they occur, and what questions you should ask your pharmacist or physician if you take rifampin.

What Rifampin Is and How It Works

Rifampin (also called rifampicin in some countries) is a member of the rifamycin class of antibiotics. It is the gold standard first-line treatment for tuberculosis and is also used for certain cases of meningococcal disease, leprosy, and other serious bacterial infections. Unlike many antibiotics that kill bacteria by targeting a single pathway, rifampin works by inhibiting bacterial RNA polymerase, an enzyme essential for bacterial gene transcription. This broad mechanism is why it is so effective against Mycobacterium tuberculosis.

However, rifampin does not limit its enzyme-inducing effects to bacteria. In the human body, rifampin is a strong inducer of hepatic cytochrome P450 enzymes—most notably CYP3A4, but also CYP2C9, CYP2C19, and others. Enzyme induction means that rifampin causes the liver to produce more of these metabolizing enzymes, which in turn metabolizes many co-administered drugs much more rapidly than normal. This accelerated metabolism typically leads to lower blood concentrations of other drugs, reducing their therapeutic effect. In rare cases, induction of certain metabolic pathways or interaction with drug transporters can lead to toxic metabolites or paradoxical toxicity.

Rifampin also acts as a pregnane X receptor (PXR) agonist, a nuclear receptor that regulates expression of drug-metabolizing enzymes and transporters. This PXR activation is part of the reason why rifampin's induction effects are so broad and persistent.

Most Serious Documented Interactions: Contraindicated Medications

The following interactions are classified as contraindicated, meaning the combination should not be used under standard circumstances. These are sourced from FDA drug labeling and represent the highest level of concern.

Clozapine + Rifampin

Clozapine is an atypical antipsychotic medication used to treat severe schizophrenia and related disorders. According to the source record, concomitant use with rifampin is not recommended due to decreased clozapine effectiveness. The mechanism is CYP3A4 induction: rifampin increases the liver's breakdown of clozapine, lowering its plasma concentration and reducing its ability to manage psychotic symptoms. For patients with schizophrenia who require clozapine, the loss of efficacy could be clinically catastrophic. If a patient on clozapine develops tuberculosis or another infection requiring rifampin, alternative antibiotics should be strongly considered, and any transition would require close psychiatric and infectious-disease monitoring.

Atovaquone (Oral Suspension) + Rifampin

Atovaquone is used to treat Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis, opportunistic infections common in immunocompromised patients, including those with HIV/AIDS. The source record specifies that concomitant administration with rifampin reduces atovaquone concentrations, and concomitant use with atovaquone oral suspension is not recommended. The mechanism is listed as "reduces atovaquone concentrations" without further detail in the source record. The practical consequence: patients taking atovaquone for a serious fungal infection would not receive adequate drug levels if rifampin is added, leaving them vulnerable to treatment failure and disease progression.

Ritonavir-Boosted Saquinavir + Rifampin

Saquinavir is a protease inhibitor used in HIV treatment; ritonavir is a booster that increases saquinavir levels by inhibiting its metabolism. According to the source record, concomitant use is contraindicated due to severe hepatocellular toxicity. The source record does not specify the mechanism. This is a striking interaction: the concern is not primarily loss of drug efficacy but direct liver damage. Hepatocellular toxicity is a severe adverse effect that can progress to liver failure. Patients on this regimen who develop tuberculosis require urgent alternative HIV and TB treatment regimens under specialist care.

Ticagrelor + Rifampin

Ticagrelor is a P2Y12 platelet inhibitor used to prevent blood clots in patients with acute coronary syndrome or those who have received coronary stents. Rifampin is a strong CYP3A inducer that substantially reduces ticagrelor exposure and decreases efficacy. The mechanism is CYP3A induction. Because ticagrelor's job is to prevent stent thrombosis or recurrent cardiac events, a loss of efficacy could precipitate a heart attack or stent closure. This is a particularly dangerous combination in a patient who has recently experienced acute coronary syndrome and also requires TB treatment.

Ranolazine (Extended-Release) + Rifampin

Ranolazine is used to improve exercise tolerance in patients with chronic angina. Rifampin, as a CYP3A inducer, should not be used with ranolazine extended-release tablets, according to the source record. Loss of ranolazine efficacy would reduce its cardioprotective benefit and worsen angina symptoms or increase ischemic risk.

Doravirine + Rifampin

Doravirine (marketed as PIFELTRO) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in HIV treatment. Co-administration decreases doravirine plasma concentrations via CYP3A induction. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO, according to the source record. This means that if a patient is on rifampin, doravirine cannot be started until at least 4 weeks after rifampin is stopped—a significant constraint in patients who need both TB and HIV treatment.

Atovaquone Oral Suspension + Rifampin (Repeated)

This is a reiterated entry in the source record (appearing twice), emphasizing the severity and specificity of the contraindication for atovaquone oral suspension.

Lorlatinib + Rifampin

Lorlatinib is a kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This interaction is particularly notable: severe hepatotoxicity occurred in healthy subjects receiving lorlatinib with rifampin, with Grade 3-4 ALT/AST increases (indicators of liver damage) in 83% of subjects. The mechanism involves both CYP3A induction and PXR agonism activation by both drugs. This is a striking finding: in a clinical trial, the vast majority of healthy volunteers who received this combination developed clinically significant liver injury. This contraindication is absolute.

Estradiol Valerate / Estradiol Valerate + Dienogest + Rifampin

Rifampin causes an 83% decrease in dienogest AUC and a 44% decrease in estradiol AUC, the source record states. These are hormonal contraceptives used for both birth control and hormone therapy. The degree of reduction (especially 83% for the progestin component) renders the contraceptive unreliable. The source record recommends that patients should not use these formulations while taking rifampin or for 28 days after discontinuation (accounting for the time it takes for rifampin's enzyme-inducing effects to wear off). Women of childbearing potential on these formulations who develop TB or another infection requiring rifampin must switch to non-hormonal or highly reliable backup contraception methods immediately.

Fosamprenavir + Rifampin

Fosamprenavir is a protease inhibitor used in HIV treatment. Concomitant use is contraindicated because rifampin decreases fosamprenavir AUC by 82%, according to the source record. The mechanism is CYP3A4 induction. An 82% reduction in drug exposure is profound and renders the antiretroviral regimen ineffective.

Understanding the Mechanism: CYP3A4 Induction and Its Consequences

Most of the documented rifampin interactions involve the mechanism of CYP3A4 enzyme induction. To understand why this is important, consider how drugs are processed in the liver. After absorption, many drugs are metabolized by liver enzymes (primarily in the cytochrome P450 family) before being eliminated from the body. CYP3A4 is the single most abundant drug-metabolizing enzyme in humans and is responsible for metabolizing roughly 50% of all prescription medications.

Normally, a drug reaches a steady-state blood concentration based on the balance between the rate at which it is absorbed and the rate at which it is metabolized and eliminated. If an enzyme inducer like rifampin is added, the liver suddenly produces more CYP3A4, and the drug is metabolized much more quickly. The steady-state blood concentration drops—sometimes dramatically. For drugs like ticagrelor, atorvastatin, or doravirine, this loss of concentration translates directly to loss of therapeutic effect. For hormonal contraceptives, the result is contraceptive failure.

In a few cases—notably lorlatinib—the interaction also involves PXR agonism. Both lorlatinib and rifampin activate the pregnane X receptor, a nuclear sensor that upregulates drug-metabolizing enzymes and transporters. When both drugs activate this pathway simultaneously, the effect on liver enzyme expression may be amplified, leading not just to loss of drug efficacy but to toxicity (in the lorlatinib case, severe hepatocellular injury).

Why Some Interactions Cause Toxicity Rather Than Loss of Effect

In most rifampin interactions, the problem is predictable: faster metabolism leads to lower drug levels and reduced efficacy. However, the lorlatinib interaction and the ritonavir-boosted saquinavir interaction demonstrate a different principle. In these cases, concomitant use leads to severe toxicity—specifically hepatocellular injury.

The exact mechanism for the lorlatinib toxicity is complex. The source record identifies both CYP3A induction and dual PXR agonism as contributors. One possibility is that PXR activation induces not only drug-metabolizing enzymes but also drug transporters and inflammatory pathways that lead to liver injury. In the lorlatinib trial, 83% of healthy subjects developed Grade 3-4 transaminase elevations—a remarkably high rate. This suggests that the interaction is not idiosyncratic but rather a direct pharmacological consequence of the combination.

For ritonavir-boosted saquinavir, the source record does not specify the mechanism of toxicity, but the presence of a documented severe hepatocellular toxicity signal is reason enough to avoid the combination entirely.

A Hypothetical Example: Tuberculosis in an HIV-Positive Patient

To illustrate why rifampin interactions matter in clinical practice, consider this scenario (hypothetical but based on realistic clinical situations): A patient with HIV is stable on doravirine (PIFELTRO) for viral suppression. Tuberculin skin testing reveals latent TB, and the patient's physician recommends starting rifampin-based anti-TB therapy. According to the source record, these two drugs cannot be used together because rifampin will reduce doravirine concentrations via CYP3A induction. Additionally, at least a 4-week cessation period is required after stopping rifampin before doravirine can be restarted.

The clinical solution would likely involve: (1) switching the patient to an alternative antiretroviral regimen that is less sensitive to CYP3A induction (if available) before starting rifampin, or (2) using TB drugs that do not induce CYP3A4 (though options are limited), or (3) carefully timing the transition to allow for washout. In some cases, specialists might use therapeutic drug monitoring to assess whether reduced doravirine levels are adequate, but this is not standard and carries risk.

This scenario underscores why it is critical for patients on any long-term medication to inform their TB specialist or infectious-disease physician of all concurrent drugs before starting rifampin.

Documented Rifampin Contraindications: Quick Reference

• Clozapine — Contraindicated; CYP3A4 induction decreases effectiveness in psychotic disorder management
• Atovaquone oral suspension — Contraindicated; reduced concentrations compromise treatment of PCP or toxoplasmosis
• Ritonavir-boosted saquinavir — Contraindicated; severe hepatocellular toxicity documented
• Ticagrelor — Contraindicated; CYP3A induction substantially reduces antiplatelet efficacy
• Ranolazine extended-release — Contraindicated; CYP3A induction reduces antianginal benefit
• Doravirine (PIFELTRO) — Contraindicated; CYP3A induction decreases HIV suppression; 4-week washout required
• Lorlatinib — Contraindicated; severe hepatocellular toxicity in 83% of trial subjects
• Estradiol valerate / estradiol valerate–dienogest — Contraindicated; 83% reduction in progestin AUC renders contraception unreliable
• Fosamprenavir — Contraindicated; 82% reduction in AUC undermines HIV treatment

Questions Patients Should Ask Their Pharmacist or Physician

If you are prescribed rifampin or are taking a medication that might interact with it, here are key questions to bring to your healthcare provider:

1. Are any of my current medications on the contraindicated list for rifampin? Ask your pharmacist to cross-check your full medication list against known rifampin interactions.
2. Do I need to stop any of my current medications before starting rifampin? Some medications (like certain antiretrovirals or hormone therapies) may need to be switched or discontinued.
3. If a medication cannot be taken with rifampin, what are safe alternatives? For many conditions, alternative drugs with less interaction potential exist.
4. How long after I finish rifampin must I wait before restarting a medication? As noted with doravirine, washout periods may be necessary because enzyme induction takes time to reverse (typically 1–2 weeks, but up to 4 weeks for some drugs).
5. Am I taking any hormone-based contraceptives? If so, you must use backup contraception during and for 28 days after rifampin to prevent unintended pregnancy.
6. Should my liver function be monitored? Given the hepatotoxicity signal with some rifampin combinations, periodic liver enzyme tests may be warranted.
7. Are there any genetic or clinical factors that make me higher-risk for a particular interaction? Patients with liver disease, for example, may be at higher risk for hepatotoxicity.

Key Takeaways

• Rifampin is a potent inducer of CYP3A4 and other hepatic drug-metabolizing enzymes, causing it to interact with at least 10 major medication classes.
• The most common consequence of rifampin interactions is reduced blood concentration of the co-administered drug and loss of therapeutic effect (as seen with antiretrovirals, anticoagulants, and hormonal contraceptives).
• In rare but serious cases (lorlatinib, ritonavir-boosted saquinavir), rifampin causes hepatocellular toxicity rather than simply reducing drug levels.
• All nine contraindicated drug combinations listed in FDA labeling should be avoided; if unavoidable, alternative regimens must be developed in consultation with specialists.
• Patients on rifampin should inform all their healthcare providers, have their medication list reviewed by a pharmacist, and use backup contraception if on hormonal birth control.

Sources

• FDA Orange Book and Drug Labeling Database (open.fda.gov) — Primary source for FDA-approved drug interactions and contraindications
• DailyMed (NIH/NLM) — Comprehensive FDA drug labeling and medication guides
• RxNorm (NIH/NLM) — Standardized drug nomenclature and interaction data
• PubMed (NIH/NLM) — Peer-reviewed literature on drug interactions and pharmacokinetics

Next Steps: Check Your Medications at checkdruginteractions.com

If you are taking rifampin or have been prescribed it, do not rely on memory to manage drug interactions. Visit checkdruginteractions.com and enter your complete medication list to identify potential interactions. The site provides clear, evidence-based summaries of documented drug pairs and their mechanisms. However, this information is educational and should always be confirmed with your pharmacist or physician before starting, stopping, or changing any medication. Your healthcare team has access to your full medical history, liver function, kidney function, and other clinical details that may affect whether a particular drug combination is safe for you personally. When in doubt, ask your pharmacist or physician directly: "Are any of my medications contraindicated with rifampin?" That simple question could prevent a serious adverse event or treatment failure.